BR112022016614A2 - Composições e métodos de uso dos mesmos para o tratamento de doenças neurodegenerativas e mitocondriais - Google Patents
Composições e métodos de uso dos mesmos para o tratamento de doenças neurodegenerativas e mitocondriaisInfo
- Publication number
- BR112022016614A2 BR112022016614A2 BR112022016614A BR112022016614A BR112022016614A2 BR 112022016614 A2 BR112022016614 A2 BR 112022016614A2 BR 112022016614 A BR112022016614 A BR 112022016614A BR 112022016614 A BR112022016614 A BR 112022016614A BR 112022016614 A2 BR112022016614 A2 BR 112022016614A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- neurodegenerative
- compositions
- treatment
- mitochondrial diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980143P | 2020-02-21 | 2020-02-21 | |
| PCT/US2021/019113 WO2021168446A1 (en) | 2020-02-21 | 2021-02-22 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016614A2 true BR112022016614A2 (pt) | 2022-12-13 |
Family
ID=77391353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016614A BR112022016614A2 (pt) | 2020-02-21 | 2021-02-22 | Composições e métodos de uso dos mesmos para o tratamento de doenças neurodegenerativas e mitocondriais |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240018146A1 (enExample) |
| EP (1) | EP4106874A4 (enExample) |
| JP (2) | JP2023515101A (enExample) |
| KR (1) | KR20220158290A (enExample) |
| CN (1) | CN115515682B (enExample) |
| AU (1) | AU2021222053A1 (enExample) |
| BR (1) | BR112022016614A2 (enExample) |
| CA (1) | CA3168531A1 (enExample) |
| CO (1) | CO2022013603A2 (enExample) |
| CR (1) | CR20220476A (enExample) |
| EC (1) | ECSP22074210A (enExample) |
| IL (1) | IL295681A (enExample) |
| MX (1) | MX2022010309A (enExample) |
| PH (1) | PH12022552518A1 (enExample) |
| WO (1) | WO2021168446A1 (enExample) |
| ZA (1) | ZA202210409B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020253561A1 (en) * | 2019-04-03 | 2021-12-02 | Mitokinin, Inc. | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
| CN119752781B (zh) * | 2025-03-04 | 2025-07-01 | 中国农业大学 | 缓解成熟卵子老化的组合物、培养液、产品及方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9604361D0 (en) * | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| TW200508224A (en) * | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| JP5231251B2 (ja) * | 2006-02-02 | 2013-07-10 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｅ１活性化酵素の阻害剤 |
| WO2008033747A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| EP2342178B1 (en) * | 2008-09-02 | 2016-09-28 | Sanofi | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| NZ710444A (en) * | 2013-02-11 | 2020-08-28 | Univ California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
| CA3067695A1 (en) * | 2017-06-21 | 2018-12-27 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
-
2021
- 2021-02-22 BR BR112022016614A patent/BR112022016614A2/pt unknown
- 2021-02-22 CR CR20220476A patent/CR20220476A/es unknown
- 2021-02-22 CN CN202180025593.5A patent/CN115515682B/zh active Active
- 2021-02-22 AU AU2021222053A patent/AU2021222053A1/en active Pending
- 2021-02-22 CA CA3168531A patent/CA3168531A1/en active Pending
- 2021-02-22 PH PH1/2022/552518A patent/PH12022552518A1/en unknown
- 2021-02-22 WO PCT/US2021/019113 patent/WO2021168446A1/en not_active Ceased
- 2021-02-22 KR KR1020227032526A patent/KR20220158290A/ko active Pending
- 2021-02-22 US US17/801,450 patent/US20240018146A1/en active Pending
- 2021-02-22 IL IL295681A patent/IL295681A/en unknown
- 2021-02-22 JP JP2022550119A patent/JP2023515101A/ja not_active Withdrawn
- 2021-02-22 EP EP21757063.9A patent/EP4106874A4/en active Pending
- 2021-02-22 MX MX2022010309A patent/MX2022010309A/es unknown
-
2022
- 2022-09-20 ZA ZA2022/10409A patent/ZA202210409B/en unknown
- 2022-09-21 CO CONC2022/0013603A patent/CO2022013603A2/es unknown
- 2022-09-21 EC ECSENADI202274210A patent/ECSP22074210A/es unknown
-
2025
- 2025-05-09 JP JP2025078577A patent/JP2025142197A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220158290A (ko) | 2022-11-30 |
| MX2022010309A (es) | 2022-11-14 |
| AU2021222053A1 (en) | 2022-09-15 |
| JP2023515101A (ja) | 2023-04-12 |
| CN115515682A (zh) | 2022-12-23 |
| EP4106874A4 (en) | 2024-03-20 |
| ECSP22074210A (es) | 2023-02-28 |
| IL295681A (en) | 2022-10-01 |
| US20240018146A1 (en) | 2024-01-18 |
| CA3168531A1 (en) | 2021-08-26 |
| EP4106874A1 (en) | 2022-12-28 |
| JP2025142197A (ja) | 2025-09-30 |
| ZA202210409B (en) | 2024-01-31 |
| CO2022013603A2 (es) | 2023-03-17 |
| CR20220476A (es) | 2023-05-31 |
| WO2021168446A1 (en) | 2021-08-26 |
| CN115515682B (zh) | 2024-06-21 |
| PH12022552518A1 (en) | 2024-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007005A2 (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
| BR112022016614A2 (pt) | Composições e métodos de uso dos mesmos para o tratamento de doenças neurodegenerativas e mitocondriais | |
| CL2021000881A1 (es) | Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel . (divisional de solicitud 201802814 | |
| DOP2022000121A (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
| BRPI0510074A (pt) | composições farmacêuticas para o tratamento de distúrbios sexuais ii | |
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| PE20200494A1 (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson | |
| UY37461A (es) | 1,2,4 – triazolonas 2,4,5 trisustituida | |
| CL2018002920A1 (es) | Nuevos derivados de pirazolopirimidina | |
| MX389700B (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| BR112014018421A8 (pt) | Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas | |
| BR112015001847A8 (pt) | Composições e tratamento para doenças e distúrbios nos olhos | |
| BR112012002578B8 (pt) | usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística | |
| CO2021002637A2 (es) | Arni variante frente a alfa-sinucleína | |
| BR112018014661A2 (pt) | composição e composição para uso | |
| CR20200546A (es) | ESTIMULADOR SELECTIVO TREG RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS | |
| BR112018074334A2 (pt) | uso de células tronco mesenquimais e partes das mesmas | |
| BR112018009941A8 (pt) | composição reguladora de crescimento vegetal com efeito sinergético | |
| MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
| UY37972A (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| CO2021013171A2 (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
| AR128163A1 (es) | Ácido láctico y análogos del mismo para uso en regular y/o promover el aumento de tejidos | |
| MX2022000781A (es) | Triterpenoides sintéticos heteroaromáticos sustituidos polarmente en c17, y métodos de uso de los mismos. | |
| BR112019001301A2 (pt) | processo para controlar plantas daninhas | |
| BR112015026973A2 (pt) | uso de vanoxerina no tratamento de arritmia cardíaca |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025016812-2 PROTOCOLO 870250070525 EM 11/08/2025 15:38. |